Literature DB >> 11452142

Expression of AhR and ARNT mRNA in cultured human endometrial explants exposed to TCDD.

J A Pitt1, L Feng, B D Abbott, J Schmid, R E Batt, T G Costich, S T Koury, D P Bofinger.   

Abstract

Endometriosis is a debilitating disease found in 10-15% of reproductive-age women and is characterized by the presence of endometrial tissue outside of the uterus. The present study characterizes the expression of AhR and ARNT mRNA in a human endometrial explant culture model in the absence and presence of TCDD exposure. In a parallel, companion study using this model, TCDD exposure was shown to induce CYP1A1 mRNA, CYP1B1 mRNA, EROD (7-ethoxyresorufin-O-deethylase) activity, and CYP1B1 protein in human endometrial explants. Explants were prepared from specimens obtained at laparoscopy or laparotomy from women undergoing surgery for tubal ligation, endometriosis, or pelvic pain unrelated to endometriosis. These specimens were a subset of the specimens used in the parallel study. The explants were cultured in medium containing 10 nM estradiol (E(2)) or 1 nM estradiol plus 500 nM progesterone (E(2) + P(4)) with or without TCDD (first 24 h). After culture, AhR and ARNT mRNA expression were quantified by RT-PCR. TCDD treatment significantly increased the expression of AhR mRNA, but not ARNT mRNA. The expression of both genes was similar for all individual explants and the ratio of AhR:ARNT mRNA expression across all samples was 1.7 to 1.8. Constitutive AhR mRNA expression was donor age dependent (increasing with age), while ARNT mRNA expression was donor age and tissue phase dependent (increased in older and proliferative phase specimens). Similar to results in the parallel study on expression of CYP1A1 mRNA, CYP1B1 mRNA, EROD activity, and CYP1B1 protein, the presence of endometriosis did not affect the expression of AhR or ARNT mRNA, either constitutively or following TCDD exposure. However, the detection of disease-specific change was limited by small sample size and variability in tissue cycle phase. The human endometrial explant culture model will be useful for future studies of the effects of dioxin-like compounds on human endometrium in relationship to cycle phase, hormonal exposure, and donor age.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11452142     DOI: 10.1093/toxsci/62.2.289

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  5 in total

1.  2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) inhibits human ovarian cancer cell proliferation.

Authors:  Yan Li; Kai Wang; Yi-Zhou Jiang; Xin-Wen Chang; Cai-Feng Dai; Jing Zheng
Journal:  Cell Oncol (Dordr)       Date:  2014-11-18       Impact factor: 6.730

2.  Auto-induction mechanism of aryl hydrocarbon receptor 2 (AHR2) gene by TCDD-activated AHR1 and AHR2 in the red seabream (Pagrus major).

Authors:  Su-Min Bak; Midori Iida; Anatoly A Soshilov; Michael S Denison; Hisato Iwata; Eun-Young Kim
Journal:  Arch Toxicol       Date:  2016-05-17       Impact factor: 5.153

Review 3.  The role of the aryl hydrocarbon receptor in the female reproductive system.

Authors:  Isabel Hernández-Ochoa; Bethany N Karman; Jodi A Flaws
Journal:  Biochem Pharmacol       Date:  2008-10-14       Impact factor: 5.858

4.  Associations between Exposure to Organochlorine Chemicals and Endometriosis: A Systematic Review of Experimental Studies and Integration of Epidemiological Evidence.

Authors:  Komodo Matta; Meriem Koual; Stéphane Ploteau; Xavier Coumoul; Karine Audouze; Bruno Le Bizec; Jean-Philippe Antignac; German Cano-Sancho
Journal:  Environ Health Perspect       Date:  2021-07-26       Impact factor: 9.031

5.  Functional expression of aryl hydrocarbon receptor on mast cells populating human endometriotic tissues.

Authors:  Laura Mariuzzi; Rossana Domenis; Maria Orsaria; Stefania Marzinotto; Ambrogio P Londero; Michela Bulfoni; Veronica Candotti; Andrea Zanello; Maurizio Ballico; Maria C Mimmi; Angelo Calcagno; Diego Marchesoni; Carla Di Loreto; Antonio P Beltrami; Daniela Cesselli; Giorgia Gri
Journal:  Lab Invest       Date:  2016-06-27       Impact factor: 5.662

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.